FDA approves new Johnson & Johnson drug for depression

Renata Sago Mar 6, 2019
HTML EMBED:
COPY
Janssen Pharmaceutica

FDA approves new Johnson & Johnson drug for depression

Renata Sago Mar 6, 2019
Janssen Pharmaceutica
HTML EMBED:
COPY

The Food and Drug Administration has approved the first new kind of drug to treat depression since Prozac hit the scene in the late 1980s. Spravato is a nasal spray from Johnson & Johnson that’s a close cousin of ketamine, an anesthetic that’s sometimes used recreationally and often known as “Special K.” Because ketamine can cause hallucinations and out-of-body experiences, the new drug must be administered in a clinical setting. The drug is designed to start working in hours instead of weeks. It’s meant to treat people who have not found relief through other antidepressants. That’s about 5 million of the 16 million Americans with depression.

Click the audio player above to hear the full story.

Correction (March 6, 2019): A previous version of this story misspelled Spravato. The text has been corrected.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.